Bioluminescence Ventures

About The Fund

Bioluminescence Ventures is a venture capital firm focused on the biotechnology sector, with a primary emphasis on investing in companies developing transformational platform technologies for first-in-class or best-in-class therapeutics programs. Headquartered in San Francisco, they are deeply invested in supporting mission-driven leaders who aim to create therapies for patients with significant unmet medical needs, acknowledging the importance of their work particularly during a period marked by both a surge in biomedical innovation and challenging financing conditions. The firm's philosophy is exemplified by its name, which signifies the guiding light of patient impact, echoing the natural phenomenon of light emitted by living organisms. Bioluminescence Ventures meticulously curates their portfolio to include breakthrough biology drug discovery platforms, genetic medicines platforms, and computational biology platforms. Led by Kouki Harasaki, Ph.D., with over 20 years of biomedical science experience, the diverse team comprises experts with deep knowledge and significant achievements in their respective fields. Other notable members include Campbell Murray, M.D., with a strong track record in venture capital and biotechnology; Chloe Kim, Ph.D., a biomedical engineer with expertise in regenerative medicine, oncology, and neuroscience; Negin Mokhtari, Ph.D., with a background in precision medicine; Andy Seid, who brings investment banking and biopharmaceutical operational expertise; and Shailaja Uttamsingh, Ph.D., with extensive experience in oncology therapy development. Bioluminescence Ventures offers financial and interdisciplinary expertise, with an investment range from $2 million to $10 million and a sweet spot of around $6 million. They focus on Seed and Series A funding rounds, striving to make a meaningful, positive impact on the lives of patients through their investments and support.